Vanguard Group Inc Kaleido Biosciences, Inc. Transaction History

Vanguard Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.05 - $1.7 $43,530 - $1.48 Million	-870,602 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.3 - $2.7 $216,820 - $450,319	-166,785 Reduced 16.08%	870,602 $1.44 Million
Q4 2021 Feb 14, 2022	BUY	$2.39 - $6.02 $2,311 - $5,821	967 Added 0.09%	1,037,387 $2.48 Million
Q3 2021 Nov 12, 2021	BUY	$5.36 - $7.99 $48,052 - $71,630	8,965 Added 0.87%	1,036,420 $5.66 Million
Q2 2021 Aug 13, 2021	BUY	$5.82 - $8.72 $5.98 Million - $8.96 Million	1,027,455 New	1,027,455 $7.64 Million

2.65K

Ticker KLDO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,622,600
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.